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PATENTS AND BIOTECHNOLOGY
PANEL COMMENTARIES'
S. Leslie Misrock'
I will begin by asking you to keep your mind on the narrow
definitions of what constitutes patentable subject matter under the
European Treaty as I discuss with you my vision of some of the
things that will happen within the next decade in biotechnology.
In my personal opinion, within the next decade-certainly by
the turn of the century-we will see genetic therapy which involves
a patient being operated on, laparoscopically removing tissue in the
operating room from a specific organ, pancreas or otherwise, while
still anesthetized, that tissue or those cells transvected with a viral
vector to move the desired gene into it, and then put back into that
patient and reimplanted so that that patient essentially will have the
gene genetically, surgically inserted into the particular patient.
The manipulative steps in all of this, the patentable subject
matter-and I'm going to focus on what the American law is-will
cover not merely the particular viral vector that is used, the pieces,
whether a new gene or a particular control gene; at the same time,
it will also cover the manipulative steps of removing tissue
laparoscopically, transvecting that tissue, and the moving it back
into the gene. Will that be patentable under United States law? In
my judgment, absolutely.
I think you will see transgenic animals-swine, for exam-
ple-capable of making human blood; you will see transgenic cows
capable of making human antibodies in their milk, such that when
the cow is inoculated to DPT (diphtheria, pertussis, etc.), that cow
will make human antibodies. No youngster has an immune system
for the first three or four months, so ingestion by a infant of milk
The following three panel commentaries were presented at the Fordham Confer-
ence on International Intellectual Property Law and Policy held at Fordham University
School of Law on April 15-16, 1993.
* Senior Partner, Pennie & Edmonds, New York, N.Y.; Massachusetts Institute of
Technology, S.B. 1955; Columbia University, A.M. 1956; Fordham University, LL.B.
1959; Niagara University, ScD. 1987.
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from that cow will in fact lead to passive immunization. Will that
transgenic animal be patentable? In my judgment, absolutely.
I think we are going to see a revolution in treatment.
Finally, as the Human Genome Project accelerates, even though
there has been a great deal of controversy about whether you
should be able to patent DNA libraries, et cetera, I think you will
see, for example, from disease states-I am particularly interested
in prostate cancer, but it will be so with every cancer-such that
from a healthy patient all the way up to one that is in the final
stages, that is terminally ill, you will get a genetic modification
map that tells you exactly where that patient is staged so that the
approach to treatment of that patient will be a systems approach
rather than the approach of using a "magic bullet," one drug, to do
something. That's inevitable.
Now, contrast some of the technologies that are talked about
with what exists in the European Patent Office-with the definition
of "morality," which is incomprehensible to me. I don't know
what the morality would be in Ireland with respect to the ability to
preclude birth upon demand; is that immoral? With respect to
using animals to prevent human disease, is that immoral? Obvious-
ly, these arguments will be raised by the Greens or otherwise. So
I see many, many problems coming about in view of John's de-
scription and the things that are happening in the European Patent
Office.
And yet, this technology is real. It will be done not only in the
United States; it will be done in Japan; it will be done at the major
pharmaceutical companies and the universities in Germany, in
France, et cetera. This revolution in biotechnology is real.
What will that lead to? I think that if there is difficulty in
getting patents to cover this technology over the next decade, it is
inevitable in this country, notwithstanding the fact that we have
joined all sorts of treaties for first-to-file procedures; that's almost
in the Dark Ages compared to obtaining patent coverage on the
subject matter I'm talking about. I think that we are going to see
what I will call a "reciprocal retribution." Will it come up in the
Patent Office in this country? No, it will come up in the courts.
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When a foreigner gets a U.S. patent--essentially plays by our rules
to get something, even though it's not patentable within his or her
own country-I think it is inevitable, when this will come up in
litigation, for a defendant within this country to try to break that
patent, one way or another. That defendant is going to argue, "We
don't have a level playing field. We ought to be able to get the
same treatment there that they get here." This is similar to what
our President is now saying with respect to opening up Japan as a
market, notwithstanding the fact that we probably make defective
goods and can't meet the Japanese requirements.
So my basic instinct is that the restrictions and constraints that
are being placed on the ability to get patent coverage on very im-
portant technologies, the restrictions that are being placed on them
by the European Patent Office, will ultimately rebound against
European companies when they come to the United States to simi-
larly get patent coverage on these same technologies.
How it will be done, I won't speculate, other than to say that
it probably will be done in the courts by imaginative, aggressive
attorneys and trial lawyers attacking the patents that issue in the
United States to such foreigners.
Now, a little bit of history with respect to some of the things
that John talked about. The Argoudelis case' in the United States
in the late 1960s sanctioned the deposit in a regulated recognized
depository of specific cells as the basis for meeting the require-
ments of section 112.
For those who are not patent lawyers, we have in our Patent
Act a section called 112,2 the first sentence of which has two claus-
es. The first clause, known as the "enablement clause," reads:
"The specification shall be written in such a clear and concise
manner as to enable the persons skilled in the art to which the
invention obtains to practice the invention." The second clause
then goes on: "And shall set forth the best mode known to the
inventor." 3
1. In re Argoudelis, 434 F.2d 1390 (C.C.P.A. 1970).
2. 35 U.S.C. § 112 (1988).
3. Id.
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Deposits are not required in the United States to meet the re-
quirements of section 112. The cases say that. The most recent
case, of course, is the Amgen v. Chugai4 case in the Federal Cir-
cuit, which is important not only for the holding that you cannot
conceive or invent a gene until you know the exact sequence of
that gene, whether you describe it or whether you have obtained
it in such a manner that it's unambiguous; but, it also held that the
failure to deposit in this particular case the transvected cells with
the gene for erythropoietin was not a fatal defect in Amgen's pat-
ent on transvected cells to make EPO.
Argoudelis came about because the applicant at that time didn't
know how to describe a new yeast, which was Saccharomyces
cerevisae, that he was using for fermentation to make ethanol.6 He
deposited with the Northern Regional Research Laboratory-which
is an agency of the Department of Agriculture-and it was a cell
depository. The Patent Office rejected his case. The then United
States Court of Customs and Patent Appeals-the predecessor to
the Federal Circuit Court of Appeals-held that this was a suffi-
cient description when this was done. Thereafter, of course, there
were deposits of unknown organisms, organisms which were used
for antibody production, and the like.
With respect to the issue of the patenting of life forms, few
people realize that we have had many earlier cases than
Chakrabarty7 in the United States, which was touted as the first
case on the patentability of living material.
There was an earlier case, called Funk Seed,8 in the U.S. Su-
preme Court which held that products of nature are not patentable.
As a matter of fact, that case more or less was distinguished by all
the subsequent cases that led to what we now do in biotechnology.
That case related to a composition comprising four Rhizobia for
nitrogen fixation. The Court never took up the question that these
4. Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200 (Fed. Cir. 1991).
5. Id.
6. In re Argoudelis, 434 F.2d 1390 (C.C.P.A. 1970).
7. Diamond v. Chakrabarty, 447 U.S. 303 (1980).
8. Funk Bros. Seed v. Kalo Inoculant Inc., 333 U.S. 127 (1948).
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four components were four living things.
The earliest case going back to living material was in the early
1920s, Chaim Weitzman's patent for the fermentation production
of butanol. Weitzman was a member of the staff of the British
Government making acetone and butanol during World War I.
These patents were then litigated in a case called Union Solvents.9
The judge concluded that there was a sufficient description of the
organism-there were no depositories in those days-held the pat-
ent valid, and speculated that he might not have reached the same
conclusion if the invention had been the organism itself. That was
only dicta, of course, and we didn't revisit that issue until it finally
came up with Chakrabarty.
Lastly, after Chakrabarty, I had a case called Hibberd'° which
we expected to lose in the Patent Office and win in the Federal
Circuit. That case held that plant seeds and plant tissue culture
were patentable subject matter within the statutory classes of sec-
tion 101, even though you could have obtained a Plant Variety
Protection Certificate.
The Patent Office took the position that the UPOV Treaty, as
they called it, was a treaty which by its very terms shrunk the
meaning of section 101 of the Patent Act. On investigation, we
found out that UPOV is not a treaty, it's an administrative agree-
ment that was never submitted to the Senate, nor has this 1991
amendment been submitted to the Senate, and, consequently, you
can get patent coverage in this country for plant seeds and plant
tissue culture. Additionally, you can get a Plant Variety Protection
Certificate on a specific species within the same genus that you
may be covering within that particular patent.
9. Guaranty Trust Co. v. Union Solvents Co., 54 F.2d 400 (D. Del. 1931), aft'd,
61 F.2d 1041 (3d Cir. 1932).
10. Ex parte Hibberd, 227 U.S.P.Q. (BNA) 443 (Bd. Pat. App. & Interferences
1985).
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Oreste Montalto*
You say that this scientific province is going so fast that many
times people do not understand it. This is also the case with mo-
rality. You talked, for instance, about the blood of a pig that could
be useful for humans. Of course, that would be a very good thing,
although I suppose some people have some doubt.
But then, we can say in defense, "What happens if I say that I
would like to have the choice whether I have a daughter or a
son"-Okay, why not? And then, after I say that, I could say, "I
would like to have a two-meter son so he can play basketball."
Why not?
In some ways the problem is a problem of a boundary, where
it is or is not. Not all people are so sensitive as you are. Of
course, we cannot stop progress. But many times there are many
people who say, "Maybe we are going too fast; it would be better
if we could stop progress." It's not possible, I understand this,
"But it would be better," some people say.
You know that in the Commission, after the Parliament's
Amendments, we are obliged to amend the Proposed Directive.
This Directive will take into account what the Parliament says.
The Parliament is very important for the Commission, because, first
of all, it has the power of motion of censure. That means that they
may vote that the Commission must resign, and so our politicized
Commissioners are sensitive to this point.
Secondly, in the Parliament there are what we call the
Greens-the ecologists-who have a lot of power. They are push-
ing the Parliament to adopt their solutions. They are a very large
majority who are opposed to the decision of EPO to patent the
"Harvard mouse." Some of the Green groups attacked their oppo-
nents in front of the High Court of Justice in Brussels when we
were waiting for the European Patent Office ruling. And so, of
course, the Commission had to take account of this.
* Principal Administrator, Directorate General Internal Market and Industrial Af-
fairs, Commission of the European Communities, Brussels, Belgium.
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It became clear that the combination of a biotechnological in-
vention should not be left out in the dark. The concept of exclu-
sion from patentability concerning the public policy and morality
was not sufficient to meet the concern of the public opinion, that
is true.
The Commission did consider whether the object of the Direc-
tive is not to talk about a moratorium for this action. They just
proposed to harmonize the Member States' patent laws. We say
we want that.
Article 2, as amended by the due date in the Directive, is just
guidelines for assisting the national patent offices and the national
courts in interpreting the concept of the patent policy and morality.
This article provides only that products be excluded from patent-
ability as being contrary to public policy and morality. We consid-
er that as just: (a) the human body or parts of the human body, per
se; (b) processes for modifying the genetic identity of the human
body for a non-therapeutic purpose which is contrary to the dignity
of man; and (c) processes for modifying the genetic identity of
animals which are likely to inflict suffering or physical handicaps
upon them without any benefit to man or animal.
The other important amendment which was introduced was the
Farmer's Rights or Privilege. It provides a possibility for the farm-
er to use part of his harvest obtained from the patented seeds that
he receives to resow his fields for his own benefit. The Commis-
sion was against that because we consider that this is against the
very essence of the property right.
Now we are discussing it in the working groups of the Council.
There are two working groups already formed, and you have al-
ready heard there is a third one. Even the new reduction has been
made about ethics. But in any case, even with that there are prob-
lems.
MR. MISROCK: Let me interrupt you for a second. Whose
ethics? The ethics of the European Patent Office members?
MR. MONTALTO: No. The working groups are made and
composed of the representatives of each Member State's govern-
ments, the patent office of each national Member State. They have
1993]
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final approval; if they say "okay" on the final, then the Council
approves it. The Council of Ministers, on the other hand, of
course, doesn't understand anything more or less about the design,
and so they await additional information.
Even with that there are problems. Some people have some
dedication that they are not convinced until now, even if there is
a reduction, there will be some amendments.
We are also waiting because the Commission last year created
a special council. This very important working group, counseling
group, will give-:maybe in the next month, its feelings about the
amended Directive. Because of the importance of this group, it
may be followed and it will be easier for us.
The other problem was the question of rights. We had a lot of
problems because many Member States, Germany and some others,
said it is not possible to accept this point. We are finally reaching
a near-compromise. It has been accepted since by many Member
States to say, "We have to find a solution, looking at it as substan-
tive rights." We do not talk about privileged farmer protection,
but, we say that in this case, for instance, patented microorganisms
might be marketed with a view to a specific application the success
of which depends on the purchaser multiplying the microorganisms
So, when the agreement is signed, the patent-holder sells the seeds
to the farmers, the purchaser has the right to reproduce the micro-
organism, and then, as a subsequent right, the right to again resow
his field. But, he cannot sell it in any way; he just can use it him-
self, but, not sell it to other people. This solution maybe will be
accepted in the future.
Finally, I want to say that we are waiting for a common posi-
tion. Denmark already has said that they are not presently able to
push to have a solution because they know that it will be very
difficult since the public opinion's sensitivity to this issue in Den-
mark is so high; so, they don't go on. It will be possible to reach
a position.
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Harold C. Wegner*
I have five brief points. Overall, we can look at the world as
a triangle comprising Japan, Europe and the United States. On all
five points Japan seems to be in a pretty good position. Japan
values biotechnology and has done a very good job of moving its
law, and shaping its law.
The first point responds immediately to the question of patent
coverage. I think in an ideal world Germany, France, Great Brit-
ain, the United States, Japan and other developed countries all
would want to have a definition of patent-eligible subject matter to
cover everything. I don't think there's any question about that
among the experts.
The problem arises in both the United States and Europe that
when we push the bubble into new technologies, we have horror
stories and fear stories. We have heard about Europe. What about
the United States? We have had the "Harvard mouse" patent is-
sued, then no further "living invention" patents for a long time.
And then, during the transition between the administrations, the
Patent Office slipped out a few more mice and other animal pat-
ents. Already, there is not only talk, but there is legislation pro-
posed by Senator Hatfield and others to have a moratorium on
animal patenting.'
There are all kinds of moral--or immoral-issues involved. I
say "immoral" because some of the opposition is purely economic.
If we have genetically manipulated cows that can produce twice or
thrice the amount of milk, isn't that good for mankind? It hurts the
farmers, but isn't that good for the starving children of the develop-
ing world?
One of the considerations I have when we address the Geneva
Harmonization Convention or otherwise, is whether we should put
* Professor of Law, George Washington University National Law Center, Wash-
ington, D.C.; Director, Intellectual Property Law Program; Northwestern University,
B.A. 1965; Georgetown University Law Center, J.D. 1969.
1. S. 387, 103d Cong., 1st Sess. (1993).
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patent eligibility aside for the time being, and get forward with all
of the other more important changes we need?
Point Two: On reciprocal retribution, I think the real loser is
not the United States, but Europe, if they don't have patent protec-
tion. Maybe the U.S. patent owner doesn't have the opportunity to
share his technology and get economic benefits from European
patent protection. But the real loser would be Europe because,
after all, if the technology cannot be exploited in Europe, and un-
less there is an exclusive position through patent or the health min-
istry or somehow, there is no way to absorb the regulatory cost of
the tens of millions of dollars and years of time for approvals that
need a patent base. So the real loser will be Europe. Europe, in
its self-interest, eventually, will find a way to introduce protection
when the time comes, when it's necessary. But for the moment,
again, I think it's dangerous for us to push the bubble on scope of
patent-eligible subject matter.
Point Three: The Proof of Utility. Judging whether an inven-
tion is useful or industrially applicable as compared to Germany or
Japan, the United States is behind. What happened is that in the
1960s, when we had the really low point of our judicial system for
patents and the Supreme Court was in its darkest hour, we had a
case called Brenner v. Manson.2
In doing a comparative study of the standard of usefulness in
the United States versus the European and Japanese standards,
America is very much behind. Here I would like to see America
learn from Europe and Japan.
Let's give an example. Let's say that I have a chemotherapeu-
tic agent. We'll take the Jolles case 3 in 1980. We had one set of
clinical trials and one compound in a broad generic definition of
compounds. We had Dr. Morell do tests on six different com-
pounds on animals, and we eventually got the genus, but only on
appeal.
Today, the U.S. Patent and Trademark Office is routinely deny-
2. 383 U.S. 519 (1966).
3. In re Jolles, 628 F.2d 1322 (C.C.P.A. 1980).
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ing patent protection for chemotherapeutic agents where there ex-
ists a broad generic definition of various possible chemotherapeutic
agents. The Patent Examiner is saying, "You should test all these
compounds." Well, if only one of the compounds is the clinical
trial compound, it's almost Mengelian to say you should test all of
these compounds for patent purposes. Are we to use people as
guinea pigs to see if the patentee should get a patent? How fool-
ish, how counterproductive. If we don't use humans, we use Rhe-
sus monkeys. Are we supposed to sacrifice dozens of monkeys to
get a generic claim? The question answers itself. I think the Unit-
ed States should learn from a comparative basis what's going on
in Europe and Japan.
Point Four: The Patentability of the Products of DNA. I share
Mr. Misrock's view that these are patentable. I also share Mr.
Richards' view.
I think the House of Lords decision on t-PA was fact-specific.
In contrast, counterpart patents in Japan were used effectively.
Genentech shut down Toyobo in the Osaka District Court.5 So, I
think fears of lack of protection are exaggerated. Japan has taken
a leadership role.
Point Five: The Scope of Protection. In all areas of technolo-
gy we look first and foremost to a claim. We chart out the claim,
the definition of what our scope of protection should be. We
talked about "Swiss cheese" claiming earlier today and how Japan
has improved its practice to fill in the holes. If you have a claim
for a range of one to ten widgets or units, I will have protection for
one, two, three, and so on to ten, and six will be included; there
will be no exclusion within the literal scope of my range.
The question then is: To what extent do we permit expansion
of the claim-the scope of protection-in biotechnology? I think
this is one of the very critical issues. It's something that we can't
summarize in 180 seconds-we probably can't summarize it in 180
hours.
4. See In re Genentech Inc.'s Patent, 1989 R.P.C. 147 (Eng. C.A.).
5. Japan's Court Rules Toyobo Infringed U.S. Medical Patent, Japan Economic
Newswire, Oct. 30, 1991, available in LEXIS, Asia Pacific Library, JEN File.
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My contribution on this is entitled Equitable Equivalents, which
deals with equitable equivalents particularly in biotechnology. 6 I
submit that a resolution of this issue, and the gaining of some com-
mon understanding among the various countries as to how equiva-
lency should be determined in this area, is of very, very great im-
portance.
Finally, I would like to thank everyone for their patience, and
particularly Mr. Montalto for speaking in a second language. I am
very grateful for your participation in this conference and for com-
ing from so far away.
6. Harold C. Wegner, Equitable Equivalents: Weighing the Equities to Determine
Patent Infringement in Biotechnology and Other Emerging Technologies, 18 RUTGERS
COMPUTER & TECH. L.J. 1 (1992).
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